Other · 5mg × 10 vials
In plain terms: VIP (Vasoactive Intestinal Peptide) is a research compound - oral, fast-acting and well studied.
VIP is a 28-amino-acid neuropeptide originally isolated from porcine intestine, part of the secretin/glucagon/GHRH superfamily (same backbone family as GLP-1 and GIP, which is why reta's structural papers cross-reference it). It signals through two G-protein-coupled receptors, VPAC1 and VPAC2, both of which activate adenylyl cyclase → cAMP → PKA. VPAC1 sits on immune cells (T cells, macrophages, dendritic cells), epithelial tissue, and the gut lining. VPAC2 dominates the lungs, smooth muscle, and parts of the central nervous system. When VIP binds, the downstream effect is potent anti-inflammatory: it suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-12), pushes T cells toward regulatory (Treg) phenotypes, calms macrophage activation, and dilates pulmonary and systemic vasculature. It is also a major regulator of the suprachiasmatic nucleus (the brain's circadian clock), which is why VIP deficiency tracks with sleep disruption and HPA-axis dysregulation in chronic illness.
The clinical relevance for Purity Peptides customers is almost entirely through one lens: Dr. Ritchie Shoemaker's CIRS (Chronic Inflammatory Response Syndrome) protocol for mold and biotoxin illness. CIRS patients show chronically depleted VIP levels alongside elevated TGF-β1, MMP-9, C4a, and VEGF. Intranasal VIP replacement, given only after upstream protocol steps are complete (binders, MARCoNS eradication, mold remediation, hormone correction), normalizes the inflammatory cascade and, in the longest-running data, restores grey matter volume in atrophied brain regions. Outside CIRS, the same anti-inflammatory mechanism is being studied in pulmonary sarcoidosis, pulmonary arterial hypertension, and severe COVID/ARDS via the synthetic version aviptadil. The plasma half-life is famously short (1-2 minutes IV), which is why dosing is intranasal or SubQ for local tissue effect, not systemic - and why the standard protocol is 4 doses per day rather than once-daily.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
VIP can cause noticeable facial flushing, transient mild headache, or lightheadedness in the first 1-3 doses (20-30% of users per literature), almost always due to vasodilation. Symptoms typically resolve within 30 minutes and tolerance builds within a few days. Customers with already-low blood pressure should start at SubQ 50 mcg once daily before trying intranasal 4× a day.
Customers must have completed prior Shoemaker steps before running VIP at this level - running VIP early in the protocol (still in a moldy building, still elevated MARCoNS, untreated binders) blunts the response and wastes the cycle. Lipase monitoring is non-negotiable here: check fasting lipase at baseline, day 14, and after any dose increase. Discontinue if lipase rises above 2× the upper limit of normal.
This is not a typical PP customer dose band. The customers who run it are deep-CIRS patients working with a Shoemaker-trained physician. Total daily VIP at 8× 100 mcg = 800 mcg/day, which is ~24 mg/month, so a 5 mg vial gets shredded fast - a VIP10 kit is the sensible size for anyone running advanced protocol.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://pmc.ncbi.nlm.nih.gov/articles/PMC3483716/) - VPAC1/VPAC2 receptor pharmacology, signaling, cAMP/PKA pathway
Read study ↗PubMedVPAC receptors: structure, molecular pharmacology and interaction with accessory proteins (PMC3415636)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3415636/)
Read study ↗PubMedVasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects (PMC1412244)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1412244/) - plasma half-life ~1 minute IV, clearance and distribution
Read study ↗PubMedRecent advances in VIP physiology and pathophysiology: focus on the GI system (PMC6743256)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/)
Read study ↗PubMedProspect of vasoactive intestinal peptide therapy for COPD/PAH and asthma (PMC3090995)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090995/)
Read study ↗PubMedThe Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Critical COVID-19 Respiratory Failure: 60-Day RCT (PMC9555831)in Critical COVID-19 Respiratory Failure: 60-Day RCT (PMC9555831)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9555831/) - safety in 200+ ICU patients
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Initial flushing/feeling-warm response: very commonly reported, almost universally settles within 3-5 doses
Energy "lift" within hours of dosing: anecdotal but consistent, attributed to circadian/HPA normalization
Sleep improvement: commonly reported within first 2 weeks (VIP's circadian role)
Brain fog clearing: most-cited subjective benefit in CIRS community, typically 2-4 weeks in
Lipase bump that resolves on dose-hold: documented, manageable with monitoring
Tolerance to flushing builds within first week
Route: intranasal (Shoemaker protocol standard) or SubQ (off-label community use)
Storage: refrigerate at 2-8°C immediately after reconstitution; use within 28-30 days. Lyophilized vials stay viable refrigerated for months. Do NOT leave reconstituted VIP at room temperature beyond a few hours; it is one of the more fragile peptides on the catalog.
Notes: For intranasal use, customers need a mucosal atomization device (MAD nasal atomizer or quality nasal spray bottle) - a standard dropper does not aerosolize properly. Reconstitute by trickling BAC water down the inside vial wall, not directly onto the lyophilized cake; swirl gently, don't shake. Some protocols use BAC with NaCl for nasal use to reduce mucosal irritation from benzyl alcohol alone, but standard 0.9% BAC is what most community users run.